Immuneel Therapeutics and THSTI advance CAR-T cell therapy and lentiviral vector manufacturing

Bengaluru-based Immuneel Therapeutics and the BRIC Translational Health Science and Technology Institute (THSTI), in Faridabad, have entered into a Memorandum of Understanding (MoU), to establish a collaboration to qualify, establish, and manage a cutting-edge facility for the Current Good Manufacturing Practice (cGMP)-compliant manufacturing of CAR-T cell therapies and Lentiviral Vectors (LVVs).

The primary goal of this collaboration is to operationalise the facility, obtain necessary regulatory approvals from the Central Drugs Standard Control Organization (CDSCO), and successfully translate academic and industrial research pipelines into clinical realities.

The partnership synergises THSTI’s newly established cleanroom facility with Immuneel’s validated commercial-grade cell therapy ecosystem. By uniting academic research capabilities with industrial operational expertise, the collaboration seeks to accelerate the translation of early-phase clinical pipelines into viable treatments for patients.

"Industry and academia collaborations are the need of the hour to bring out the best of India's scientific and translational capabilities. This partnership represents a vital step in operationalising clinical pipelines, and it begins as one of the many such collaborations needed in India to ensure we can compete and lead on a global scale." said Dr Lakshmikanth Gandikota, Chief Scientific Officer, Immuneel Therapeutics.